Type 1 Diabetes Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Sept. 28, 2011 - PRLog -- GlobalData estimates that the global type 1 diabetes therapeutics market was worth $2,331m in 2010 after increasing at a Compound Annual Growth Rate (CAGR) of 17.4% during the period 2005-2010. During 2010-2018 the market is expected to record a CAGR of 8.7%, to reach $4,552.4m by 2018. The growth recorded in the type 1 diabetes therapeutics market during 2005-2010 was primarily attributed to the increased prevalence of diabetes mellitus in the US, EU5 (France, Germany, Italy, Spain and the UK) and Japan, an increase in the average cost of therapy with the existing treatment options available, an increased treatment seeking rate and increased awareness of diabetes. GlobalData’s analysis suggests that the US has the highest patient share of EU5 and Japan.

The type 1 diabetes therapeutics market is expected to grow significantly during 2010-2018 due to the expected launch of drugs with novel mechanisms of action and newer formulations of existing product which will increase patient compliance through convenience of administration, such as Degludec (insulin degludec and insulin aspart) a new generation ultra-long-acting insulin, Oral-lyn an oral spray formulation of human insulin and DiaPep277 (human heat shock protein 60) an immunomodulator peptide which preserves beta-cell function and arrests beta cell destruction. During the forecast period patent the patents of certain insulins are set to expire which will affect market growth. Humalog (insulin lispro), NovoLog (insulin aspart) and Lantus (insulin glargine) are insulin preparations of biologic origin. The biosimilars will be available at competitive prices provided guidelines for the launch of biosimilars are implemented.

GlobalData’s analysis suggests that approximately 35% of the global type 1 diabetes therapeutics market is unserved. There is currently no approved drug available to retard the destruction of beta cells (islet of Langerhans). Current products are able to achieve better glycemic control in the majority of patients, but controlling diabetes-related symptoms is generally painful and requires strict compliance to a treatment regime. They are relatively inconvenient in terms of the mode of delivery, which impacts patient compliance. All marketed products display adverse reactions such as hypoglycemia, local injection site reactions and allergic reactions. Therefore, the market also faces unmet need in terms of product safety. A strong pipeline will drive the market in the forecast period, with 80 molecules in various phases of pre-clinical and clinical development. Phase III has 14 molecules, Phase II has 25 molecules, Phase I has 22 molecules and pre-clinical has 19 molecules.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

The late stages of pipeline classes are ultra rapid-acting insulin analogues and oral insulin analogues, which if launched successfully, will improve patient compliance. Degludec is a new-generation ultra-long acting basal insulin, which showed potentially substantial benefits for type 1 diabetic patients Oral insulin analogue, Oral-lyn is a prandial (meal time) insulin to replace the failing rapid secretion of insulin, non-invasive therapy and a cost effective alternative to the traditional insulin formulation. DiaPep277 is an anti-CD3 monoclonal antibody immunomodulator peptide which preserves the beta-cell function and arrests beta cell destruction.

GlobalData, the industry analysis specialist, has released its new report, “Type 1 Diabetes Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Type 1 Diabetes Therapeutics market. The report identifies the key trends shaping and driving the global Type 1 Diabetes Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Type 1 Diabetes Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Type...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.